Weight-loss drug makers are competing fiercely to expand their share in China, the world's second-largest pharmaceutical market. Due to local regulations strictly prohibiting direct advertising of prescription drugs, these companies have shifted to indirect outreach strategies, organizing obesity awareness campaigns at subway stations, gyms, and football stadiums.
This is part of efforts to attract Chinese consumers, where rates of overweight and obesity have been rising rapidly in recent years. Placing health messages and obesity risk warnings in busy public venues is seen as an effective way to build awareness without running afoul of stringent advertising rules.
Industry experts note that instead of directly promoting products, drugmakers are focusing on educating the public about the harms of obesity, thereby creating latent demand for treatment drugs. This strategy not only helps companies stay compliant with the law but also projects a positive image to consumers.
Analysts believe that with its large population and a growing middle class increasingly concerned about health, China represents a promising market for weight-loss drugs. Competition between foreign and domestic pharmaceutical companies is expected to intensify in the coming period.
